Trastuzumab is the first humanized monoclonal antibody targeting the HER2 receptor, directed against the extracellular domain of the receptor and leading to blockage of the MAP kinase signaling pathways and the PI3K-Akt pathway, which diminishes the cell cycle, decreases tumor cell proliferation, and stimulates innate cellular immunity via ADCC. Here, AKT1 is linked to neoplasm.